Local production of dermatologicals continues to be extremely limited in Azerbaijan. The Leyner Melhemi brand, owned by Bakikimyaeczasenaye ASC, is expected to represent the most significant local presence in dermatologicals.
Nizoral is expected to increase its brand share and lead in dermatologicals in 2020. The brand, owned by Janssen Pharmaceutica NV, benefits from a proven record of effectiveness and strong brand awareness among consumers which has seen its sales increase in the review period.
Urbanisation and a growing amount of sedentary work, in combination with high-fat-content local food, results in widespread haemorrhoid problems among consumers. Although retail current value sales of haemorrhoid treatments are not expected to grow in 2020, demand is expected to remain constant as Azerbaijani consumers continue to suffer the effects of unhealthy and sedentary lifestyles.
Nappy (diaper) rash treatment is expected to continue to exhibit growth throughout the forecast period, maintaining a high level of growth throughout. This product will continue to be dominated by Bayer AG in 2020, and their dominance will represent a significant obstacle to other competitors in the category going into the forecast period.
As in haemorrhoid treatments, vaginal antifungals has also diversified significantly over the course of the review period and is expected to continue to show retail current value growth in the forecast period, supported by the promotion of local distributors’ promotions. Aiming to lead vaginal antifungals, Nizhfarm also released three brands towards the end of the review period: Geksikon, Livarol and Vitaprost.
Further retail value growth is anticipated over the forecast period as consumers look to self-medication for dermatological complaints, especially minor ones, in order to save on visits to professionals, such as cosmetologists. The exchange rate will be the major factor contributing to dermatologicals’ performance over the forecast period.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Azerbaijan with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Azerbaijan, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page